Shengda Pharmaceutical Co.,Limited is a pharmaceutical intermediates and APIs GMP factory, Shengdapharm has GMP production base in Jiangxi and Shenzhen multifunctional pharmaceutical R & D center and the Shenzhen / India / usa three trade service center, GMP production base in Jiangxi production work...
Nintedanib (BIBF-1120), an orally administered intracellular tyrosine kinase inhibitor (TKI) initially developed as an antitumor agent, has antifibrotic properties and was one of the first drugs (along with the antifibrotic pirfenidone) to be approved for the treatment of IPF in the EU and USA; ...
Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology 22: 1171-1178, No. 6, Aug 2017. Available from: URL: http://doi.org/10.1111/resp.13024 -USA Article PubMed Google Scholar Download references Rights and permissions ...
Moreover, Pirfenidone has been demonstrated to have a significant statistical impact on the decline of forced vital capacity (FVC), and it is better than other antifibrotic drugs [9,10]; so, it was approved for the treatment of IPF in Europe in 2011 and in the USA in 2014. The introdu...
Moreover, Pirfenidone has been demonstrated to have a significant statistical impact on the decline of forced vital capacity (FVC), and it is better than other antifibrotic drugs [9,10]; so, it was approved for the treatment of IPF in Europe in 2011 and in the USA in 2014. The introdu...